Company Profile: OncoTAb, Inc.

CED Life Science Conference 2017 - Lightning Round & Innovation Room

www.oncotab.com                                                                  
Sub-sector: Biotech and Pharmaceutical                                                                
Year Founded: 2011

COMPANY PROFILE
OncoTAb, Inc. was founded by a Mayo Clinic alumna, Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The technology platform on which these products are being developed is a patented monoclonal antibody (TAB004). OncoTAb has a worldwide exclusive license to this technology platform. The company has launched its first product: Agkura™ Personal Score, a simple, non-invasive blood test as a supplemental test for women with dense breast tissue whose cancers are missed by mammography 50% of the time. OncoTAb has a CLIA registered laboratory and is seeking partnerships/licensing opportunities to accelerate adoption in the US (TAM $ 7.8 Billion) and also offer this test in China and Japan where over 70% of the women have dense breast tissue. OncoTAb has also initiated development of cancer therapies on the basis of two National Cancer Institute awards.

FOUNDERS/MANAGEMENT TEAM
Rahul Puri PhD, CEO
Pinku Mukherjee PhD, CSO

KEY MILESTONES TO DATE

  • Funding: $2.7MM inequity, debt, and non-dilutive
  • Launched Agkura Personal Score, an adjunct to mammography, May 2016
  • Received NCI grant for Pancreatic Cancer Therapy, June 2016
  • Received NCI contract for Targeted Radionuclide Therapy for Triple Negative Breast Cancer, September 2016
  • Antibody on track to be fully humanized by Q1, 2017

POWERED BY
NC Biotechnology Center, SBTDC, SCORE, Southeast Bio, UNC Charlotte Office of Technology Transfer

CONTACT
Rahul Puri
rahul@oncotab.com
Charlotte, NC

Learn more about the CED Life Science Conference.